Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.

Fornecker LM, Muller L, Bertrand F, Paul N, Pichot A, Herbrecht R, Chenard MP, Mauvieux L, Vallat L, Bahram S, Cianférani S, Carapito R, Carapito C.

Sci Rep. 2019 Jan 29;9(1):895. doi: 10.1038/s41598-018-37273-4.

2.

BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo.

Schleiss C, Ilias W, Tahar O, Güler Y, Miguet L, Mayeur-Rousse C, Mauvieux L, Fornecker LM, Toussaint E, Herbrecht R, Bertrand F, Maumy-Bertrand M, Martin T, Fournel S, Georgel P, Bahram S, Vallat L.

Sci Rep. 2019 Jan 24;9(1):701. doi: 10.1038/s41598-018-36853-8.

3.

Tuberculosis and atypical mycobacterial infections in ruxolitinib treated patients with primary or secondary myelofibrosis or polycythemia vera.

Lescuyer S, Ledoux MP, Gravier S, Natarajan-Amé S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R.

Int J Infect Dis. 2019 Jan 10. pii: S1201-9712(19)30012-8. doi: 10.1016/j.ijid.2019.01.002. [Epub ahead of print]

4.

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.

Seidel D, Meißner A, Lackner M, Piepenbrock E, Salmanton-García J, Stecher M, Mellinghoff S, Hamprecht A, Durán Graeff L, Köhler P, Cheng MP, Denis J, Chedotal I, Chander J, Pakstis DL, Los-Arcos I, Slavin M, Montagna MT, Caggiano G, Mares M, Trauth J, Aurbach U, Vehreschild MJGT, Vehreschild JJ, Duarte RF, Herbrecht R, Wisplinghoff H, Cornely OA, Bachmann B, Borchert K, Burchardt A, Chakrabarti A, Christopeit M, Fasih N, Hekmat K, Hernández Rupérez B, Kemmerling B, Kessel J, Jyoti Kindo A, Klimko N, Krause R, Lass-Flörl C, Levesque E, Lockhart S, Steinmann J, Maritati A, Markiefka B, Martín Gómez MT, Meis J, Oksi J, Pagano L, Ramos Martinez A, Reischies F, Soler Palacin P, Vermeulen E.

Crit Rev Microbiol. 2019 Jan 10:1-21. doi: 10.1080/1040841X.2018.1514366. [Epub ahead of print]

PMID:
30628529
5.

Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda LL, Croos-Dabrera R, Fredericks C, Thompson GR 3rd.

Clin Infect Dis. 2018 Oct 5. doi: 10.1093/cid/ciy827. [Epub ahead of print]

PMID:
30289478
6.

Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.

Maertens J, Selleslag D, Heinz WJ, Saulay M, Rahav G, Giladi M, Aoun M, Kovanda L, Kaufhold A, Engelhardt M, Cornely OA, Herbrecht R, Ullmann AJ.

Mycoses. 2018 Nov;61(11):868-876. doi: 10.1111/myc.12831. Epub 2018 Aug 13.

PMID:
30035825
7.

Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.

Herbrecht R, Kuessner D, Pooley N, Posthumus J, Escrig C.

Curr Med Res Opin. 2018 Dec;34(12):2187-2195. doi: 10.1080/03007995.2018.1502659. Epub 2018 Aug 17.

PMID:
30022696
8.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.

J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.

PMID:
29975624
9.

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study.

Gangneux JP, El Cheikh J, Herbrecht R, Yakoub-Agha I, Quiniou JB, Caillot D, Michallet M.

Infect Dis Ther. 2018 Sep;7(3):309-325. doi: 10.1007/s40121-018-0203-4. Epub 2018 Jun 9.

10.

18F-FDG PET/CT for invasive fungal infection in immunocompromised patients.

Leroy-Freschini B, Treglia G, Argemi X, Bund C, Kessler R, Herbrecht R, Imperiale A.

QJM. 2018 Sep 1;111(9):613-622. doi: 10.1093/qjmed/hcy128.

PMID:
29917146
11.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.

Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.

PMID:
29897404
12.

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Herbrecht R, Ojeda-Uribe M, Kientz D, Fohrer C, Bohbot A, Hinschberger O, Liu KL, Remy E, Ernst C, Lin JS, Corash L, Cazenave JP.

Vox Sang. 2018 May 21. doi: 10.1111/vox.12663. [Epub ahead of print]

PMID:
29786866
13.

Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.

Ledoux MP, Denis J, Nivoix Y, Herbrecht R.

J Mycol Med. 2018 Mar;28(1):15-22. doi: 10.1016/j.mycmed.2018.02.002. Epub 2018 Mar 16. Review.

PMID:
29551442
14.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

PMID:
29544767
15.

Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.

Denis J, Ledoux MP, Nivoix Y, Herbrecht R.

J Mycol Med. 2018 Mar;28(1):8-14. doi: 10.1016/j.mycmed.2018.02.005. Epub 2018 Mar 11. Review.

PMID:
29534853
16.

Evaluation of Two Commercial Real-Time PCR Kits for Aspergillus DNA Detection in Bronchoalveolar Lavage Fluid in Patients with Invasive Pulmonary Aspergillosis.

Denis J, Forouzanfar F, Herbrecht R, Toussaint E, Kessler R, Sabou M, Candolfi E, Letsher-Bru V.

J Mol Diagn. 2018 May;20(3):298-306. doi: 10.1016/j.jmoldx.2017.12.005. Epub 2018 Feb 19.

PMID:
29471112
17.

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.

Goh JG, Ravikumar S, Win MS, Cao Q, Tan AL, Lim JHJ, Leong W, Herbrecht R, Troke PF, Kullberg BJ, Netea MG, Chng WJ, Dan YY, Chai LYA.

Cell Microbiol. 2018 Mar;20(3). doi: 10.1111/cmi.12798. Epub 2017 Dec 20.

PMID:
29088499
18.

Brain abscesses caused by Cladophialophora bantiana in a lung transplant patient: A case report and review of the literature.

Gschwend A, Dégot T, Denis J, Sabou AM, Jeung MY, Zapata E, Porzio M, Renaud-Picard B, Herbrecht R, Kessler R.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12787. Epub 2017 Nov 7. Review.

PMID:
28994171
19.

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

J Clin Med. 2017 Sep 26;6(10). pii: E92. doi: 10.3390/jcm6100092.

20.

Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature.

Gallais F, Denis J, Koobar O, Dillenseger L, Astruc D, Herbrecht R, Candolfi E, Letscher-Bru V, Sabou M.

BMC Infect Dis. 2017 Aug 2;17(1):535. doi: 10.1186/s12879-017-2646-8. Review.

21.

FungiScope -Global Emerging Fungal Infection Registry.

Seidel D, Durán Graeff LA, Vehreschild MJGT, Wisplinghoff H, Ziegler M, Vehreschild JJ, Liss B, Hamprecht A, Köhler P, Racil Z, Klimko N, Sheppard DC, Herbrecht R, Chowdhary A, Cornely OA, FungiScope Group.

Mycoses. 2017 Aug;60(8):508-516. doi: 10.1111/myc.12631.

PMID:
28730644
22.

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.

Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva JA, Garbino J, Yan JL, Aram J, Capparella MR, Conte U, Schlamm H, Swanson R, Herbrecht R.

J Antimicrob Chemother. 2017 Aug 1;72(8):2368-2377. doi: 10.1093/jac/dkx116.

23.

Assessment of high-priced systemic antifungal prescriptions.

Poulat C, Nivoix Y, Launoy A, Lutun P, Bachellier P, Rohr S, Woehl ML, Levêque D, Bru V, Herbrecht R, Gourieux B.

Med Mal Infect. 2017 Oct;47(6):382-388. doi: 10.1016/j.medmal.2017.03.004. Epub 2017 Apr 13.

PMID:
28412043
24.

New pharmacological opportunities for the treatment of invasive mould diseases.

Ledoux MP, Toussaint E, Denis J, Herbrecht R.

J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i48-i58. doi: 10.1093/jac/dkx033.

PMID:
28355467
25.

18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation.

Muller N, Kessler R, Caillard S, Epailly E, Hubelé F, Heimburger C, Namer IJ, Herbrecht R, Blondet C, Imperiale A.

Nucl Med Mol Imaging. 2017 Mar;51(1):58-68. doi: 10.1007/s13139-016-0461-6. Epub 2016 Nov 28.

26.

Idiosyncratic drug-induced neutropenia & agranulocytosis.

Andrès E, Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

QJM. 2017 Jan 9. pii: hcw220. doi: 10.1093/qjmed/hcw220. [Epub ahead of print]

PMID:
28069912
27.

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R.

Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.

28.

Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases.

Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R, Andrès E.

Drugs Real World Outcomes. 2016 Dec;3(4):393-399.

29.

Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):433-42. doi: 10.1093/cid/ciw444.

30.

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE.

Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.

31.

Magnetic Resonance Imaging of Cerebral Aspergillosis: Imaging and Pathological Correlations.

Marzolf G, Sabou M, Lannes B, Cotton F, Meyronet D, Galanaud D, Cottier JP, Grand S, Desal H, Kreutz J, Schenck M, Meyer N, Schneider F, Dietemann JL, Koob M, Herbrecht R, Kremer S.

PLoS One. 2016 Apr 20;11(4):e0152475. doi: 10.1371/journal.pone.0152475. eCollection 2016.

32.

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators.

Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.

PMID:
26969258
33.

Multimodality Diagnosis Approach of Cardiac Aspergillosis.

El Ghannudi S, Imperiale A, Dégot T, Germain P, Trinh A, Petean R, Le Van Quyen P, Chenard MP, Letscher-Bru V, Kessler R, Herbrecht R.

Echocardiography. 2016 Apr;33(4):663-5. doi: 10.1111/echo.13165. Epub 2016 Jan 20. No abstract available.

PMID:
26787141
34.

Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF).

Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V, Cassaing S, Chouaki T, Kauffmann-Lacroix C, Poirier P, Toubas D, Augereau O, Rocchi S, Garcia-Hermoso D, Bretagne S; French Mycosis Study Group.

Clin Microbiol Infect. 2016 Sep;22(9):810.e1-810.e8. doi: 10.1016/j.cmi.2015.12.006. Epub 2015 Dec 17.

35.

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.

Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.

PMID:
26684607
36.

Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.

Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Sèze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS.

Joint Bone Spine. 2016 May;83(3):330-4. doi: 10.1016/j.jbspin.2015.07.002. Epub 2015 Oct 1.

PMID:
26433710
37.

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, Corby A, Aurran-Schleinitz T, Gastaud L, Talbot A, Leprêtre S, Mahe B, Payet C, Soussain C, Bonnet C, Vincent L, Lissandre S, Herbrecht R, Kremer S, Leblond V, Fornecker LM.

Haematologica. 2015 Dec;100(12):1587-94. doi: 10.3324/haematol.2015.133744. Epub 2015 Sep 18. Review.

38.

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.

Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, Herbrecht R, Wolff M, Ribaud P, Lortholary O; French Mycosis Study Group.

J Antimicrob Chemother. 2015 Nov;70(11):3116-23. doi: 10.1093/jac/dkv236. Epub 2015 Aug 27.

PMID:
26316385
39.

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.

Goy A, Kalayoglu Besisik S, Drach J, Ramchandren R, Robertson MJ, Avivi I, Rowe JM, Herbrecht R, Van Hoof A, Zhang L, Cicero S, Fu T, Witzig T.

Br J Haematol. 2015 Aug;170(4):496-503. doi: 10.1111/bjh.13456. Epub 2015 Apr 28.

40.

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J.

Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17.

41.

Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway.

Alhosin M, León-González AJ, Dandache I, Lelay A, Rashid SK, Kevers C, Pincemail J, Fornecker LM, Mauvieux L, Herbrecht R, Schini-Kerth VB.

Sci Rep. 2015 Mar 11;5:8996. doi: 10.1038/srep08996.

42.

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA.

Ann Intern Med. 2015 Jan 20;162(2):81-9. doi: 10.7326/M13-2508. Erratum in: Ann Intern Med. 2015 Mar 17;162(6):463.

PMID:
25599346
43.

[Erratum to "Medication adverse events: Impact of pharmaceutical consultations during the hospitalization of patients" [Ann. Pharm. Fr. 72 (2014) 440-450].]

Santucci R, Levêque D, Herbrecht R, Fischbach M, Gérout AC, Untereiner C, Bouayad-Agha K, Couturier F.

Ann Pharm Fr. 2015 Jan 8;73(2):160-161. doi: 10.1016/j.pharma.2014.12.002. [Epub ahead of print] French. No abstract available.

PMID:
25578947
44.

Impact of clinical pharmacy services in a hematology/oncology inpatient setting.

Delpeuch A, Leveque D, Gourieux B, Herbrecht R.

Anticancer Res. 2015 Jan;35(1):457-60.

PMID:
25550587
45.

Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis.

Cornely OA, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M.

Mycoses. 2015 Jan;58(1):58-64. doi: 10.1111/myc.12274.

PMID:
25530265
46.

[Medication adverse events: Impact of pharmaceutical consultations during the hospitalization of patients].

Santucci R, Levêque D, Herbrecht R, Fischbach M, Gérout AC, Untereiner C, Bouayad-Agha K, Couturier F.

Ann Pharm Fr. 2014 Nov;72(6):440-50. doi: 10.1016/j.pharma.2014.05.003. Epub 2014 Jul 8. French. Erratum in: Ann Pharm Fr. 2015 Jan 8;73(2):160-161.

PMID:
25438655
47.
48.

Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim.

Duval C, Boucher S, Moulin JC, Gourieux B, Mauvieux L, Leveque D, Herbrecht R.

Anticancer Res. 2014 Nov;34(11):6747-8.

PMID:
25368285
49.

Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis.

Strassel C, Kubovcakova L, Mangin PH, Ravanat C, Freund M, Skoda RC, Denis CV, Dupuis A, Herbrecht R, Gachet C, Lanza F.

Thromb Haemost. 2015 Feb;113(2):414-25. doi: 10.1160/TH14-08-0667. Epub 2014 Oct 9.

PMID:
25298269
50.

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF.

PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014.

Supplemental Content

Loading ...
Support Center